PIK3CA and cancer: It should then not be too surprising that targeting upstream activators of this pathway showed limited effectiveness when tested in trials in patients with advanced cancers (5,7) since even if the major clone initially responds, the presence of minor clones with autonomous activation of the PI3K pathway could result in ultimate treatment failure.